A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Phase 2

Completed

• Conditions: Anxiety Disorders

• Registration Number: NCT00543920
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2002-08
• Primary Completion: 2003-02
• Study Completion: 2003-02
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-11
• Last Update Submitted: 2015-11-25
• Last Update Posted: 2015-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Diagnosis of General Anxiety Order

Read More

Exclusion Criteria

• Women who are pregnant or breast-feeding
• History of severe drug reaction
• History of severe drug withdrawal symptoms such as seizures or delirium
• Disease of cardiovascular system
• Disease of the liver, kidneys, endocrine system, metabolic system or eyes
• History of seizures or seizure disorder
• History of drug or alcohol abuse

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL